The Correlation Between Lipoprotein(a) Elevations and the Risk of Recurrent Cardiovascular Events in CAD Patients with Different LDL-C Levels

Overview

Journal BMC Cardiovasc Disord

Publisher Biomed Central

Specialty Cardiology & Vascular Diseases

Date 2022 Apr 16

PMID 35428179

Authors

Lijun Zhu

Jiamin Zheng

Beibei Gao

Xiangbo Jin

Ying He

Liang Zhou

Jinyu Huang

Affiliations

Soon will be listed here.

Abstract

Background: Lipoprotein(a) [Lp(a)] elevation is an important risk factor for coronary artery disease (CAD). However, the correlation between Lp(a) elevations and the risk of recurrent cardiovascular events in patients with established cardiovascular disease is controversial. Some studies have shown that Low-density lipoprotein cholesterol (LDL-C) levels may influence the association between Lp(a) and cardiovascular risk. Our study aims to explore the correlation between Lp(a) elevations and cardiovascular risk in patients with different LDL-C levels.

Methods: We included 516 patients who received coronary stents due to acute coronary syndrome (ACS) and followed them for three years. They were divided into low-Lp(a) group and high-Lp(a) group according to Lp(a) levels, and the incidence of major adverse cardiovascular events (MACE) and acute coronary events (ACE) was compared between the two groups. Then the patients were divided into three subgroups (S1:LDL-C ≥ 1.8 mmol/L; S2:1.4 ≤ LDL-C < 1.8 mmol/L; S3:LDL-C < 1.4 mmol/L). The correlation between Lp(a) elevations and cardiovascular risk in different subgroups was analysed by Cox proportional hazards models.

Results: The incidence of MACE and ACE in the high-Lp(a) group was significantly higher than those in the low-Lp(a) group (P < 0.05). Lp(a) elevations had independent prognostic value from the statistical point of view (MACE: HR = 1.63, 95%CI = 1.12-2.38, P = 0.012; ACE: HR = 1.70, 95%CI = 1.03-2.81, P = 0.037). Subgroup analysis showed that Lp(a) elevations increased cardiovascular risk when LDL-C ≥ 1.4 mmol/L. However, this correlation no longer existed when LDL-C levels were very low (< 1.4 mmol/L) (MACE: HR = 0.49, 95%CI = 0.17-1.42, P = 0.186; ACE: HR = 0.68, 95%CI = 0.18-2.61, P = 0.570).

Conclusions: Lp(a) elevations are associated with recurrent cardiovascular events when LDL-C levels are high, but this association may change when LDL-C levels are extremely low. CAD patients with combination of LDL-C ≥ 1.4 mmol/L and Lp(a) elevations shall be considered as high-risk groups and require further medication for the reduction of their LDL-C levels.

Citing Articles

Interaction Between Lipoprotein(a) and Other Lipid Molecules: A Review of the Current Literature.

Sheashaa H, Mousa H, Abbas M, Farina J, Awad K, Pereyra M Biomolecules. 2025; 15(2).

PMID: 40001465 PMC: 11853184. DOI: 10.3390/biom15020162.

Lipoprotein(a) and thromboembolism: current state of knowledge and unsolved issues.

Konieczynska M, Natorska J, Zabczyk M, Undas A Arch Med Sci. 2025; 20(6):1770-1783.

PMID: 39967936 PMC: 11831339. DOI: 10.5114/aoms/197357.

Lipoprotein (a): Underrecognized Risk with a Promising Future.

Manzato M, Wright R, Jaffe A, Vasile V Rev Cardiovasc Med. 2024; 25(11):393.

PMID: 39618878 PMC: 11607505. DOI: 10.31083/j.rcm2511393.

LDL-C and hs-CRP Jointly Modify the Effect of Lp(a) on 5-Year Death in Patients With Percutaneous Coronary Intervention.

Li J, Yan K, Zhu P, Tang X, Yang Y, Gao R Clin Cardiol. 2024; 47(10):e70025.

PMID: 39428896 PMC: 11491544. DOI: 10.1002/clc.70025.

Frequency of lipoprotein(a) testing and its levels in Pakistani population.

Batool H, Khan M, Ain Q, Chughtai O, Khan M, Khan M Glob Cardiol Sci Pract. 2024; 2024(4):e202437.

PMID: 39351483 PMC: 11439424. DOI: 10.21542/gcsp.2024.37.

References

Cegla J, France M, Marcovina S, Neely R . Lp(a): When and how to measure it. Ann Clin Biochem. 2020; 58(1):16-21. PMC: 7791270. DOI: 10.1177/0004563220968473. View

Gencer B, Rigamonti F, Nanchen D, Vuilleumier N, Kern I, Aghlmandi S . Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes. Eur J Clin Invest. 2019; 49(7):e13117. DOI: 10.1111/eci.13117. View

Nordestgaard B, Chapman M, Ray K, Boren J, Andreotti F, Watts G . Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010; 31(23):2844-53. PMC: 3295201. DOI: 10.1093/eurheartj/ehq386. View

Jellinger P, Handelsman Y, Rosenblit P, Bloomgarden Z, Fonseca V, Garber A . AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017; 23(Suppl 2):1-87. DOI: 10.4158/EP171764.APPGL. View

Tada H, Takamura M, Kawashiri M . Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease. J Atheroscler Thromb. 2019; 26(7):583-591. PMC: 6629747. DOI: 10.5551/jat.RV17034. View

Erqou S, Kaptoge S, Perry P, Di Angelantonio E, Thompson A, White I . Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009; 302(4):412-23. PMC: 3272390. DOI: 10.1001/jama.2009.1063. View

ODonoghue M, Fazio S, Giugliano R, Stroes E, Kanevsky E, Gouni-Berthold I . Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2018; 139(12):1483-1492. DOI: 10.1161/CIRCULATIONAHA.118.037184. View

Tsimikas S, Gordts P, Nora C, Yeang C, Witztum J . Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2019; 41(24):2275-2284. DOI: 10.1093/eurheartj/ehz310. View

Ren Y, Pan W, Li X, Wang S, Lv H, Yu Y . The Predictive Value of Lp(a) for Adverse Cardiovascular Event in ACS Patients With an Achieved LDL-C Target at Follow Up After PCI. J Cardiovasc Transl Res. 2021; 15(1):67-74. DOI: 10.1007/s12265-021-10148-2. View

10.

Cai A, Li L, Zhang Y, Mo Y, Li Z, Mai W . Baseline LDL-C and Lp(a) elevations portend a high risk of coronary revascularization in patients after stent placement. Dis Markers. 2013; 35(6):857-62. PMC: 3866824. DOI: 10.1155/2013/472845. View

11.

Collet J, Thiele H . The 'Ten Commandments' for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020; 41(37):3495-3497. DOI: 10.1093/eurheartj/ehaa624. View

12.

Maher V, Brown B, Marcovina S, Hillger L, Zhao X, Albers J . Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA. 1995; 274(22):1771-4. View

13.

Mach F, Baigent C, Catapano A, Koskinas K, Casula M, Badimon L . 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; 41(1):111-188. DOI: 10.1093/eurheartj/ehz455. View

14.

Clarke R, Peden J, Hopewell J, Kyriakou T, Goel A, Heath S . Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009; 361(26):2518-28. DOI: 10.1056/NEJMoa0902604. View

15.

. [Chinese expert consensus on lipid management of very high-risk atherosclerotic cardiovascular disease patients]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020; 48(4):280-286. DOI: 10.3760/cma.j.cn112148-20200121-00036. View

16.

. [2016 Chinese guideline for the management of dyslipidemia in adults]. Zhonghua Xin Xue Guan Bing Za Zhi. 2016; 44(10):833-853. DOI: 10.3760/cma.j.issn.0253-3758.2016.10.005. View

17.

Thiele H, Desch S, de Waha S . [Acute myocardial infarction in patients with ST-segment elevation myocardial infarction : ESC guidelines 2017]. Herz. 2017; 42(8):728-738. DOI: 10.1007/s00059-017-4641-7. View

18.

Dai H, Much A, Maor E, Asher E, Younis A, Xu Y . Global, regional, and national burden of ischaemic heart disease and its attributable risk factors, 1990-2017: results from the Global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes. 2020; 8(1):50-60. PMC: 8728029. DOI: 10.1093/ehjqcco/qcaa076. View

19.

Hess C, Clare R, Neely M, Tricoci P, Mahaffey K, James S . Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. Am Heart J. 2017; 187:194-203. DOI: 10.1016/j.ahj.2017.01.016. View

20.

ODonoghue M, Morrow D, Tsimikas S, Sloan S, Ren A, Hoffman E . Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol. 2013; 63(6):520-7. PMC: 3945105. DOI: 10.1016/j.jacc.2013.09.042. View